Gapping up
In reaction to strong earnings/guidance:
- KFRC +14.3%, SCOR +13.4%, JCOM +13.1%, MESA +11.7%, NIO +9.6%, ICUI +9% (also signs long-term US distribution deal with GRFS), QRTEA +8.7%, KAMN +7.1%, DHT +6.1%, GSKY +5.1%, STAY +4.8%, ADPT +4.7%, IART +4.5%, LITE +4.5%, HUYA +4.1%, ADUS +3.6%, TME +3.5%, ADVM +3.2%, SPG +2.8%, CSOD +2.8%, MAC +2.2%, TCO +2.1%, WES +2%, CSPR +1.8%, ATCO +1.8%, NTR +1.7%, RUN +1.1%, IMOS +1.1%
M&A news:
- PFNX +63.4% (to be acquired by LGND)
- MVC +16.5% (to merge with BBDC)
Other news:
- EQ +22.1% (announces "positive" interim data with itolizumab in EQUATE study)
- PLX +11.1% (announced that the FDA has accepted the Biologics License Application (BLA) and granted Priority Review designation for pegunigalsidase alfa for the proposed treatment of adult patients with Fabry disease)
- CUK +7.4% (announces upcoming voyage cancellations for three Seabourn ships)
- ASPN +5.3% (secures broad injunctions against Chinese manufacturers; German court again finds Chinese aerogel products infringe Aspen's European patents)
- TME +3.5% (Tencent Music and Universal Music announce multi-year extension of licensing agreement)
- QGEN +3.3% (announces new commercialization and distribution agreement with HTGM)
- LH +3.3% (announced details of a no charge antibody testing program in response to federal health authorities' request to increase donations of COVID-19 blood plasma) ADVM +3.2% (positive interim data from Phase 1 Trial of ADVM-022)
- TECH +3.1% (announced the release of the SARS-CoV-1/2 Spike RBD LlaMABody Recombinant Antibody)
- BMY +2.5% (reports CheckMate -649, a phase 3 trial evaluating Opdivo (nivolumab) plus chemotherapy vs. chemotherapy, meets primary endpoints)
- QDEL +1.7% (says Maryland now allows for COVID testing even without symptoms)
- CFG +1.6% (Fed has decided not to change prior decision on DFAST ruling)
Analyst comments:
- MCRB +10.1% (upgraded to Buy from Hold at Jefferies)
- HSBC +4.3% (upgraded to Equal-Weight from Underweight at Morgan Stanley)
- GOCO +2.5% (initiated with an Outperform at William Blair)
- FRT +1.1% (upgraded to In-line from Underperform at Evercore ISI)